Höhn AK, Brambs CE, Hiller GGR, May D, Schmoeckel E, Horn LC (2021) 2020 WHO classification of female genital tumors. Geburtshilfe Frauenheilkd 81:1145–1153. https://doi.org/10.1055/a-1545-4279

Article  PubMed  PubMed Central  Google Scholar 

Prat J, D’Angelo E, Espinosa I (2018) Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. Hum Pathol 80:11–27. https://doi.org/10.1016/j.humpath.2018.06.018

Article  CAS  PubMed  Google Scholar 

Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17–48. https://doi.org/10.3322/caac.21763

Article  PubMed  Google Scholar 

Kurman RJ, Shih IM (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34:433–443. https://doi.org/10.1097/PAS.0b013e3181cf3d79

Article  PubMed  PubMed Central  Google Scholar 

Kurman RJ, Shih IM (2016) The dualistic model of ovarian carcinogenesis revisited, revised, and expanded. Am J Pathol 186:733–747. https://doi.org/10.1016/j.ajpath.2015.11.011

Article  PubMed  PubMed Central  Google Scholar 

Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474:609–615. https://doi.org/10.1038/nature10166

Article  CAS  Google Scholar 

Kurman RJ, Carcangiu ML, Herrington CS, Young RH (2014) WHO classification of tumours of female reproductive organs. Lyon: International Agency for Research on Cancer https://doi.org/10.1055/a-1545-4279

Kuhn E, Ayhan A, Shih IEM, Seidman JD, Kurman RJ (2013) Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium. Eur J Cancer 49:3839–49. https://doi.org/10.1016/j.ejca.2013.08.011

Article  PubMed  Google Scholar 

Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R et al (2012) TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma–evidence supporting the clonal relationship of the two lesions. J Pathol 226:421–426. https://doi.org/10.1002/path.3023

Article  CAS  PubMed  Google Scholar 

Soslow RA, Han G, Park KJ, Garg K, Olvera N, Spriggs DR et al (2012) Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol 25:625–636. https://doi.org/10.1038/modpathol.2011.183

Article  CAS  PubMed  Google Scholar 

Köbel M, Piskorz AM, Lee S, Lui S, LePage C, Marass F et al (2016) Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol Clin Res 2:247–258. https://doi.org/10.1002/cjp2.53

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wong RW, Palicelli A, Hoang L, Singh N (2020) Interpretation of p16, p53 and mismatch repair protein immunohistochemistry in gynaecological neoplasia. Diagn Histopathol 26:257–277. https://doi.org/10.1016/j.mpdhp.2020.03.002

Article  Google Scholar 

Park E, Han H, Choi SE, Park H, Woo HY, Jang M et al (2022) p53 immunohistochemistry and mutation types mismatching in high-grade serous ovarian cancer. Diagnostics (Basel) 12:579. https://doi.org/10.3390/diagnostics12030579

Article  CAS  PubMed  Google Scholar 

Streel S, Salmon A, Dheur A, Bours V, Leroi N, Habran L et al (2023) Diagnostic performance of immunohistochemistry compared to molecular techniques for microsatellite instability and p53 mutation detection in endometrial cancer. Int J Mol Sci 24:4866. https://doi.org/10.3390/ijms24054866

Article  CAS  PubMed  PubMed Central  Google Scholar 

Köbel M, Kalloger SE, Carrick J, Huntsman D, Asad H, Oliva E et al (2009) A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 33:14–21. https://doi.org/10.1097/PAS.0b013e3181788546

Article  PubMed  Google Scholar 

Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH et al (2001) Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 195:451–456. https://doi.org/10.1002/path.1000

Article  CAS  PubMed  Google Scholar 

Piek JM, van Diest PJ, Zweemer RP, Kenemans P, Verheijen RH (2001) Tubal ligation and risk of ovarian cancer. Lancet 358:844. https://doi.org/10.1016/S0140-6736(01)05992-X

Article  CAS  PubMed  Google Scholar 

Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A et al (2007) A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 211:26–35. https://doi.org/10.1002/path.2091

Article  CAS  PubMed  Google Scholar 

Bowtell DD (2010) The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 10:803–808. https://doi.org/10.1038/nrc2946

Article  CAS  PubMed  Google Scholar 

Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C et al (2008) Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 5:e232. https://doi.org/10.1371/journal.pmed.0050232

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsang YT, Deavers MT, Sun CC, Kwan SY, Kuo E, Malpica A et al (2013) KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. J Pathol 231:449–456. https://doi.org/10.1002/path.4252

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zarei S, Wang Y, Jenkins SM, Voss JS, Kerr SE, Bell DA (2020) Clinicopathologic, immunohistochemical, and molecular characteristics of ovarian serous carcinoma with mixed morphologic features of high-grade and low-grade serous carcinoma. Am J Surg Pathol 44:316–328. https://doi.org/10.1097/PAS.0000000000001419

Article  PubMed  Google Scholar 

Coleman RL, Hennessy BT, Coleman RL, Markman M. Ovarian Cancer Version 1.2020—March 11, 2020; NCCN: Plymouth Meeting, PA, USA, 2020. Available online: https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf (accessed on 29 January 2021).

Peres LC, Cushing-Haugen KL, Köbel M, Harris HR, Berchuck A, Rossing MA et al (2019) Invasive epithelial ovarian cancer survival by histotype and disease stage. J Natl Cancer Inst 111:60–68. https://doi.org/10.1093/jnci/djy071

Article  PubMed  Google Scholar 

Krämer P, Talhouk A, Brett MA, Chiu DS, Cairns ES, Scheunhage DA et al (2020) Endometrial cancer molecular risk stratification is equally prognostic for endometrioid ovarian carcinoma. Clin Cancer Res 26:5400–5410. https://doi.org/10.1158/1078-0432.CCR-20-1268

Article  PubMed  Google Scholar 

Parra-Herran C, Lerner-Ellis J, Xu B, Khalouei S, Bassiouny D, Cesari M et al (2017) Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups. Mod Pathol 30:1748–1759. https://doi.org/10.1038/modpathol.2017.81

Article  CAS  PubMed  Google Scholar 

Van Gool IC, Ubachs JEH, Stelloo E, de Kroon CD, Goeman JJ, Smit VTHBM et al (2018) Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf’s clothing. Histopathology 72:248–258. https://doi.org/10.1111/his.13338

Article  PubMed  Google Scholar 

Hoang LN, McConechy MK, Köbel M, Anglesio M, Senz J, Maassen M et al (2015) Polymerase epsilon exonuclease domain mutations in ovarian endometrioid carcinoma. Int J Gynecol Cancer 25:1187–1193. https://doi.org/10.1097/IGC.0000000000000492

Article  PubMed  Google Scholar 

Leskela S, Romero I, Cristobal E, Pérez-Mies B, Rosa-Rosa JM, Gutierrez-Pecharroman A et al (2020) Mismatch repair deficiency in ovarian carcinoma: frequency, causes, and consequences. Am J Surg Pathol 44:649–656. https://doi.org/10.1097/PAS.0000000000001432

Article  PubMed  Google Scholar 

Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S et al (2015) Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol 1:1319–1323. https://doi.org/10.1001/jamaoncol.2015.2151